

# Synthesis and 12-Helical Secondary Structure of $\beta$ -Peptides Containing (2*R*,3*R*)-Aminoproline


Emilie A. Porter, Xifang Wang, Margaret A. Schmitt, and Samuel H. Gellman\*

Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706

gellman@chem.wisc.edu

Received July 30, 2002


## ABSTRACT



(2*R*,3*R*)-Aminoproline, a pyrrolidine-based  $\beta$ -amino acid, was synthesized and incorporated into hexa- $\beta$ -peptide 4. This residue confers water solubility when the ring nitrogen is protonated and allows for 12-helix formation in aqueous solution. Circular dichroism spectra display the 12-helical signature, and 12-helical structure was confirmed by 2D NMR analysis.

Oligomers that are capable of taking on well-defined conformations in solution (“foldamers”) have received much attention in recent years.<sup>1</sup> One class of foldamers,  $\beta$ -peptides, has been studied by several research groups.<sup>2</sup> Recently,  $\beta$ -peptides have been found to display useful biological functions.<sup>3</sup> Some of the biologically active  $\beta$ -peptides that have come from our laboratory display a 12-helical secondary structure. The 12-helix is promoted by  $\beta$ -amino acids that

are constrained by five-membered rings, such as *trans*-aminocyclopentanecarboxylic acid (ACPC, Figure 1).<sup>4,5</sup> This



**Figure 1.** Protected monomers for 12-helical  $\beta$ -peptides.

helix is defined by 12-membered ring hydrogen bonds [ $C=O(i) \rightarrow N-H(i+3)$ ] and has approximately 2.6 residues per turn. The 12-helix is well-suited for biological applica-

(1) (a) Gellman, S. H. *Acc. Chem. Res.* **1998**, *31*, 173–180. (b) Barron, A. E.; Zuckermann, R. N. *Curr. Opin. Chem. Biol.* **1999**, *3*. (c) Hill, D. J.; Mio, M. J.; Prince, R. B.; Hughes, T. S.; Moore, J. S. *Chem. Rev.* **2001**, *101*, 3893–4011.

(2) (a) Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. *Chem. Rev.* **2001**, *101*, 3219–3232. (b) Gademann, K.; Hintermann, T.; Schreiber, J. V. *Curr. Med. Chem.* **1999**, *6*, 905–925. (c) Claridge, T. D. W.; Goodman, J. M.; Moreno, A.; Angus, D.; Barker, S. F.; Taillefumier, C.; Watterson, M. P.; Fleet, G. W. J. *Tetrahedron Lett.* **2001**, *42*, 4251–4255.

(3) (a) Werder, M.; Hauser, H.; Abele, S.; Seebach, D. *Helv. Chim. Acta* **1999**, *82*, 1774–1783. (b) Gademann, K.; Ernst, M.; Hoyer, D.; Seebach, D. *Angew. Chem., Int. Ed.* **1999**, *38*, 1223–1226. (c) Hamuro, Y.; Schneider, J. P.; DeGrado, W. F. *J. Am. Chem. Soc.* **1999**, *121*, 12200–12201. (d) Porter, E. A.; Wang, X.; Lee, H. S.; Weisblum, B.; Gellman, S. H. *Nature* **2000**, *404*, 565. (e) Gademann, K.; Ernst, M.; Seebach, D.; Hoyer, D. *Helv. Chim. Acta* **2000**, *83*, 16–33. (f) Gademann, K.; Seebach, D. *Helv. Chim. Acta* **2001**, *84*, 2924–2937. (g) Gademann, K.; Kimmerlin, T.; Hoyer, D.; Seebach, D. *J. Med. Chem.* **2001**, *44*, 2460–2468. (h) Liu, D. H.; DeGrado, W. F. *J. Am. Chem. Soc.* **2001**, *123*, 7553–7559. (i) Arvidsson, P. I.; Frackenhohl, J.; Ryder, N. S.; Liechty, B.; Petersen, F.; Zimmermann, H.; Camenisch, G. P.; Woessner, R.; Seebach, D. *ChemBioChem* **2001**, *2*, 771. (j) Umezawa, N.; Gelman, M. A.; Haigis, M. C.; Raines, R. T.; Gellman, S. H. *J. Am. Chem. Soc.* **2002**, *124*, 368–369. (k) LePlae, P. R.; Fisk, J. D.; Porter, E. A.; Weisblum, B.; Gellman, S. H. *J. Am. Chem. Soc.* **2002**, *124*, 6820–6821. (l) Rueping, M.; Mahajan, Y.; Sauer, M.; Seebach, D.

*ChemBioChem* **2002**, *3*, 257–259. (m) Porter, E. A.; Weisblum, B.; Gellman, S. H. *J. Am. Chem. Soc.* **2002**, *124*, 7324–7330. (n) Arnold, U.; Hinderaker, M. P.; Nilsson, B. L.; Huck, B. R.; Gellman, S. H.; Raines, R. T. *J. Am. Chem. Soc.* **2002**, *124*, 8522–8523.


(4) (a) Appella, D. H.; Christianson, L. A.; Klein, D. A.; Powell, D. R.; Huang, X. L.; Barchi, J. J.; Gellman, S. H. *Nature* **1997**, *387*, 381–384. (b) Appella, D. H.; Christianson, L. A.; Klein, D. A.; Richards, M. R.; Powell, D. R.; Gellman, S. H. *J. Am. Chem. Soc.* **1999**, *121*, 7574–7581. (c) Another type of constrained  $\beta$ -amino acid has been reported to promote the 12-helix: Winkler, J. D.; Piatnitski, E. L.; Mehlmann, J.; Kasperek, J.; Axelsen, P. H. *Angew. Chem., Int. Ed.* **2001**, *40*, 743–745.

tions because its dimensions are similar to those of the  $\alpha$ -helix found in proteins.

We have previously shown that 12-helices can form in water when a pyrrolidine monomer, *trans*-3-aminopyrrolidine-4-carboxylic acid (APC, Figure 1), is incorporated.<sup>6</sup> APC confers water solubility by virtue of protonation of the ring nitrogen. To have maximum flexibility in the design of  $\beta$ -peptides for biological applications, we need a pool of constrained  $\beta$ -amino acids with variety in the type or orientation of peripheral functional groups. Here we describe the synthesis of an isomer of APC, (2*R*,3*R*)-aminoproline (AP), which differs from APC in the position of the pyrrolidine nitrogen relative to the substituents but nevertheless promotes 12-helix formation.


Our synthesis of enantiomerically pure AP in a protected form is outlined in Scheme 1. We were not able to synthesize

**Scheme 1.** Synthesis of Fmoc-AP(Boc) **1**




Fmoc-AP(Boc) **1** by a route analogous to those used for Fmoc-APC(Boc)<sup>7</sup> and Fmoc-ACPC;<sup>8</sup> the starting ketoester **2** would not react with methylbenzylamine to form the enamine necessary for the key reductive amination, even under Dean–Stark conditions (Scheme 2). The synthesis we employed for **1** is analogous to a route previously described

**Scheme 2**



for ACPC by Tilley et al.<sup>9</sup> The stereocenters are set by a nonfermenting baker's yeast reduction<sup>10</sup> of known ketoester **2**;<sup>11</sup> the reaction proceeds in approximately 89% ee (determined by chiral HPLC) and excellent yield. However, as a result of tedious workup, the yield tends to decrease upon reaction scale-up. The absolute configuration of the hydroxy-ester product has been established by Cooper et al.<sup>11b</sup> The alcohol can be transformed to an azide by a Mitsunobu reaction with hydrazoic acid in excellent yield. Gomez-Vidal and Silverman have reported using DPPA in the synthesis of the methyl ester version of the molecule.<sup>12</sup> While DPPA is a more convenient reagent than hydrazoic acid, in this case the yields are only moderate (60–75%), and an elimination byproduct inseparable from the desired azide (~10%) is formed during the DPPA reaction. The azide is reduced to an amine with tin(II) chloride and protected with a carboxybenzyl group. The ester is hydrolyzed and the carboxybenzyl group is replaced by a fluorenylmethoxy-carbonyl group for solid-phase synthesis.

Compound **1** was used along with Fmoc-ACPC and Fmoc-APC(Boc) in standard automated solid-phase peptide synthesis of several  $\beta$ -peptide hexamers, including **3** and **4** (Figure 2), with HBTU activation. Treatment with 95% TFA



**Figure 2.**  $\beta$ -peptides **3** and **4**. Curved arrows superimposed on **4** indicate NOEs between residues that are not adjacent in sequence (CD<sub>3</sub>OH). The dashed arrow indicates an NOE that is ambiguous because of resonance overlap.

cleaved the  $\beta$ -peptide from the resin and deprotected the pyrrolidine nitrogens. Although the baker's yeast reduction

(5) *cis*-ACPC promotes strand formation: Martinek, T. A.; Tóth, G. K.; Vass, E.; Hollósi, M.; Fülöp, F. *Angew. Chem., Int. Ed.* **2002**, *41*, 1718–1721.

(6) Wang, X.; Espinosa, J. F.; Gellman, S. H. *J. Am. Chem. Soc.* **2000**, *122*, 4821–4822.

(7) Lee, H. S.; LePlae, P. R.; Porter, E. A.; Gellman, S. H. *J. Org. Chem.* **2001**, *66*, 3597–3599.

(8) LePlae, P. R.; Umezawa, N.; Lee, H. S.; Gellman, S. H. *J. Org. Chem.* **2001**, *66*, 5629–5632.


(9) Tilley, J. W.; Danho, W.; Shiuey, S.; Kulesha, I.; Swistok, J.; Makofske, R.; Michalewsky, J.; Triscari, J.; Nelson, D.; Weatherford, S.; Madison, V.; Fry, D.; Cook, C. *J. Med. Chem.* **1992**, *35*, 3774.

(10) Seebach, D.; Roggo, S.; Maetzke, T.; Braunschweiger, H.; Cercus, J.; Krieger, M. *Helv. Chim. Acta* **1987**, *70*, 1605–1615.

(11) (a) Blake, J.; Willson, C. D.; Rapoport, H. *J. Am. Chem. Soc.* **1964**, *86*, 5293–5299. (b) Cooper, J.; Gallagher, P. T.; Knight, D. W. *J. Chem. Soc., Perkin Trans. 1* **1993**, 1313–1317.

in the preparation of **1** proceeded with only 89% ee, the  $\beta$ -peptides described here are diastereomerically pure after HPLC purification. Initial examination of hexamer **3** in CD<sub>3</sub>OH via NMR revealed extensive overlap among <sup>1</sup>H resonances, which precluded further analysis. Hexamer **4** was designed to show enhanced <sup>1</sup>H resonance dispersion; **4** contains three different types of  $\beta$ -amino acid residue, while **3** contains only two. Two-dimensional NMR (ROESY) data for **4** in CD<sub>3</sub>OH allowed us to identify eight NOEs between residues that are not adjacent in the sequence, all of which are consistent with at least partial population of the 12-helical conformation (no NOE inconsistent with the 12-helix was detected). Two types of nonsequential NOEs were observed, C $\beta$ H<sub>i</sub>  $\rightarrow$  NH<sub>i+2</sub> (four of five detected; one is ambiguous) and C $\beta$ H<sub>i</sub>  $\rightarrow$  C $\alpha$ H<sub>i+2</sub> (all four detected). These results show that the AP residue promotes 12-helix formation in solution, since many of the NOEs involve or span the AP residues.

$\beta$ -Peptide hexamers **3** and **4** were also characterized by circular dichroism for comparison with APC/ACPC  $\beta$ -peptides<sup>4</sup> and all-ACPC  $\beta$ -peptides.<sup>7</sup> Hexamer **4** showed the characteristic CD signature for the 12-helix in both methanol and aqueous buffer (10 mM Tris, pH 7.2, Figure 3).<sup>13</sup> Very similar data were obtained for **3** (not shown). The CD spectrum of **4** has a maximum at 204 nm and a minimum at



**Figure 3.** CD spectra of **4** (0.2 mM) in methanol and in aqueous buffer.

222 nm in methanol, and the maximum is blue-shifted to 201 nm in aqueous solution. The CD spectrum in methanol is more intense, suggesting a higher population of 12-helix in methanol than in aqueous solution. Helix stabilization by alcohols relative to water has been reported previously both for  $\beta$ -peptides<sup>2a</sup> and conventional  $\alpha$ -peptides.<sup>14</sup> It is significant that hexamer **4** forms a 12-helix in aqueous solution, because  $\alpha$ -peptides with six amino acids, as well as most short  $\beta$ -peptides comprised of acyclic residues,<sup>15</sup> do not form helices in water. We have previously shown that  $\beta$ -peptides consisting of ACPC, APC and related residues form the 12-helix in water with only six residues.<sup>4,16</sup>

The AP residue reported here adds to our monomer pool for the synthesis of functionalized 12-helical  $\beta$ -peptides. AP has recently been incorporated into a 17-residue  $\beta$ -peptide that displays antimicrobial properties.<sup>3m</sup> We anticipate that the AP residue will be valuable in the development of additional  $\beta$ -peptides with useful properties.

**Acknowledgment.** This research was supported by the NIH (GM56414). E.A.P. was supported in part by a Biotechnology Training Grant (NIH 5 T32 GM08349). M.A.S. was supported in part by a Biophysics Training Grant. CD data were obtained in the Biophysics Instrumentation Facility at UW-Madison, supported by NSF. NMR spectra were obtained in the Chemistry Instrument Center, supported by NSF and NIH.

**Supporting Information Available:** Experimental procedure for compound **1**, oligomer synthesis, and 2D NMR data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0266370

(12) Gomez-Vidal, J. A.; Silverman, R. B. *Org. Lett.* **2001**, 3, 2481–2484.

(13) Applequist, J.; Bode, K. A.; Appella, D. H.; Christianson, L. A.; Gellman, S. H. *J. Am. Chem. Soc.* **1998**, 120, 4891–4892.

(14) Creighton, T. E. *Proteins: Structures and Molecular Properties*, 2nd ed.; W. H. Freeman and Company: New York, 1993.

(15) A few  $\beta$ -peptides containing exclusively acyclic residues have been reported to be 14-helical in aqueous solution. (a) A seven-residue  $\beta$ -peptide: Gung, B. W.; Zou, D.; Stalcup, A. M.; Cottrell, C. E. *J. Org. Chem.* **1999**, 64, 2176–2177. (b) A seven-residue  $\beta$ -peptide stabilized by salt bridges: Arvidsson, P. I.; Rueping, M.; Seebach, D. *Chem. Commun.* **2001**, 649–650. (c) A 15-residue  $\beta$ -peptide stabilized by salt bridges: Cheng, R. P.; DeGrado, W. F. *J. Am. Chem. Soc.* **2001**, 123, 5162–5163.

(16) Lee, H. S.; Syud, F. A.; Wang, X.; Gellman, S. H. *J. Am. Chem. Soc.* **2001**, 123, 7721–7722.